AFFILIATIONS
1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, shanghai, China
3 The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, suzhou, China
4 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, shanghai, China
6 Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, suzhou, China
7 Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, suzhou, China
8 Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, suzhou, China
9 Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, suzhou, China
10 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
11 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
12 Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, suzhou, China
13 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, shanghai, China
14 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
ABSTRACT
NUP98 rearrangements (NUP98-r) define a rare, aggressive subtype of acute myeloid leukemia (AML) recognized by the 2022 World Health Organization (WHO) and International Consensus Classification (ICC) but lacking specific risk stratification in the 2022 European LeukemiaNet (ELN) recommendations. To unbiasedly assess their prognostic impact, we performed comprehensive whole transcriptome RNA sequencing in a large consecutive multicenter cohort comprising 2,829 adult non-acute promyelocytic leukemia (non-APL) AML patients diagnosed between January 2019 and June 2025.
After exclusion of untreated cases and those without RNA sequencing data, 108 NUP98-r patients (3.8%) were identified. Eighteen distinct fusion partners were detected. The most frequent fusion was NUP98::NSD1 (56.5%), followed by NUP98::HOXA9 (15.7%), along with two novel fusions (NUP98::CDCA7L, and NUP98::EEF1A1). NUP98-r patients were younger (median age 43 vs. 47 years, P=0.015) and had higher white blood cell counts (median 35.6 vs. 12.5 ×10?/L, P<0.001). Their overall survival (OS) approximated that of the adverse-risk group, yet marked heterogeneity existed across fusion partners. NUP98::HOXA9 conferred favorable survival approaching the favorable-risk group (2-year OS 88.9%), whereas NUP98::NSD1 and other fusions were associated with poor outcomes resembling adverse-risk disease. Notably, allogeneic hematopoietic stem cell transplantation in first remission consistently improved survival in NUP98-r patients, with the benefit particularly pronounced in the NUP98::NSD1 subgroup (2-year OS: 91.3% with transplantation vs. 48.2% without).
As one of the largest cohorts to date, this study establishes NUP98-r as a prognostically relevant entity with marked fusion-partner heterogeneity and supports early transplantation, especially for NUP98::NSD1 patients.
DISCLOSURES
Yang Miao: No relevant conflicts of interest to declare.